Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547534 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00547534 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 31 participants.
The verdict
NCT00547534, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
Interventions
- DRUG rituximab
- DRUG bendamustine
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547534
The ClinicalTrials.gov registry entry for NCT00547534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which rituximab is the first listed.
NCT00547534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547534 about?
NCT00547534 is a clinical study titled "Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma". The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
What is the current status of trial NCT00547534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2007-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00547534?
The interventions under investigation include: rituximab (DRUG), bendamustine (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00547534?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.